Procter & Gamble Health Limited (PGHL.NS)
INR 5467.25
(0.04%)
INR 5467.25
(0.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.07 Billion INR | -10.62% |
| 2022 | 3.42 Billion INR | 19.12% |
| 2021 | 2.8 Billion INR | 8.44% |
| 2020 | 2.63 Billion INR | 22.62% |
| 2019 | 2.08 Billion INR | 10.14% |
| 2018 | 1.96 Billion INR | -10.32% |
| 2017 | 2.18 Billion INR | 38.63% |
| 2016 | 1.56 Billion INR | 77.91% |
| 2015 | 887.2 Million INR | 48.93% |
| 2014 | 595.7 Million INR | -24.87% |
| 2013 | 792.9 Million INR | -37.86% |
| 2012 | 1.27 Billion INR | 23.21% |
| 2011 | 1.03 Billion INR | -11.61% |
| 2010 | 1.17 Billion INR | 12.66% |
| 2009 | 1.03 Billion INR | 6.68% |
| 2008 | 974.8 Million INR | -8.44% |
| 2007 | 1.06 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.17 Billion INR | 288.61% |
| 2023 Q3 | 700.3 Million INR | -31.11% |
| 2023 FY | - INR | -10.62% |
| 2023 Q2 | 1.01 Billion INR | 7.33% |
| 2023 Q1 | 947.1 Million INR | 86.88% |
| 2023 Q4 | 482.5 Million INR | -31.1% |
| 2022 Q1 | 942.4 Million INR | 37.34% |
| 2022 Q2 | 1.14 Billion INR | 21.94% |
| 2022 Q3 | 825 Million INR | -28.21% |
| 2022 Q4 | 506.8 Million INR | -38.57% |
| 2022 FY | - INR | 19.12% |
| 2021 Q1 | 811.1 Million INR | 59.48% |
| 2021 Q3 | 711.2 Million INR | 6.88% |
| 2021 Q4 | 686.2 Million INR | -3.52% |
| 2021 Q2 | 665.4 Million INR | -17.96% |
| 2021 FY | - INR | 8.44% |
| 2020 Q3 | 339.7 Million INR | -64.04% |
| 2020 Q2 | 944.7 Million INR | 11.38% |
| 2020 FY | - INR | 22.62% |
| 2020 Q1 | 848.2 Million INR | 59.76% |
| 2020 Q4 | 508.6 Million INR | 49.72% |
| 2019 Q4 | 530.91 Million INR | -9.62% |
| 2019 FY | - INR | 10.14% |
| 2019 Q3 | 587.39 Million INR | 19.82% |
| 2019 Q2 | 490.23 Million INR | -1.76% |
| 2019 Q1 | 499 Million INR | -8.5% |
| 2018 Q4 | 545.38 Million INR | 8.82% |
| 2018 Q2 | 153.45 Million INR | -73.63% |
| 2018 Q1 | 581.96 Million INR | 18.04% |
| 2018 FY | - INR | -10.32% |
| 2018 Q3 | 501.19 Million INR | 226.61% |
| 2017 Q3 | 471.38 Million INR | -2.19% |
| 2017 FY | - INR | 38.63% |
| 2017 Q4 | 493.02 Million INR | 4.59% |
| 2017 Q2 | 481.93 Million INR | -14.92% |
| 2017 Q1 | 566.44 Million INR | 104.66% |
| 2016 Q3 | 293.04 Million INR | -23.96% |
| 2016 Q4 | 276.77 Million INR | -5.55% |
| 2016 FY | - INR | 77.91% |
| 2016 Q1 | 491.97 Million INR | 48.41% |
| 2016 Q2 | 385.36 Million INR | -21.67% |
| 2015 Q2 | 318.69 Million INR | 25.21% |
| 2015 FY | - INR | 48.93% |
| 2015 Q4 | 331.5 Million INR | 46.41% |
| 2015 Q3 | 226.42 Million INR | -28.95% |
| 2015 Q1 | 254.52 Million INR | -19.31% |
| 2014 Q4 | 315.42 Million INR | 76.41% |
| 2014 FY | - INR | -24.87% |
| 2014 Q1 | 294.24 Million INR | -15.36% |
| 2014 Q2 | -137.44 Million INR | -146.71% |
| 2014 Q3 | 178.8 Million INR | 230.09% |
| 2013 Q4 | 347.65 Million INR | 281.01% |
| 2013 FY | - INR | -37.86% |
| 2013 Q2 | 15.39 Million INR | -94.28% |
| 2013 Q1 | 269.13 Million INR | -3.5% |
| 2013 Q3 | 91.24 Million INR | 492.69% |
| 2012 Q4 | 278.9 Million INR | 21.54% |
| 2012 Q3 | 229.46 Million INR | -51.16% |
| 2012 FY | - INR | 23.21% |
| 2012 Q2 | 469.81 Million INR | 30.48% |
| 2012 Q1 | 360.05 Million INR | 10.41% |
| 2011 Q4 | 326.1 Million INR | 58.12% |
| 2011 Q1 | 281.91 Million INR | 0.0% |
| 2011 Q2 | 316.16 Million INR | 12.15% |
| 2011 Q3 | 206.24 Million INR | -34.77% |
| 2011 FY | - INR | -11.61% |
| 2010 FY | - INR | 12.66% |
| 2009 FY | - INR | 6.68% |
| 2008 FY | - INR | -8.44% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sigachi Industries Limited | 883.39 Million INR | -248.02% |
| Ind-Swift Limited | 1.06 Billion INR | -188.658% |
| Bajaj HealthCare Limited | 406.23 Million INR | -656.798% |
| Sakar Healthcare Limited | 393.26 Million INR | -681.757% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 95.024% |
| Innova Captab Limited | 1.66 Billion INR | -84.282% |
| Divi's Laboratories Limited | 25.43 Billion INR | 87.91% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -30.448% |
| Morepen Laboratories Limited | 1.72 Billion INR | -78.128% |
| Mankind Pharma Limited | 28.09 Billion INR | 89.057% |
| Sequent Scientific Limited | 549.8 Million INR | -459.185% |
| Wanbury Limited | 985.49 Million INR | -211.967% |
| Laurus Labs Limited | 8 Billion INR | 61.599% |
| Nectar Lifesciences Limited | 1.53 Billion INR | -100.21% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 55.202% |
| Alembic Limited | 1.11 Billion INR | -175.4% |
| Hikal Limited | 2.69 Billion INR | -14.195% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 68.031% |
| Neuland Laboratories Limited | 4.74 Billion INR | 35.251% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 67.065% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 72.898% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -17.947% |
| Themis Medicare Limited | 562.6 Million INR | -446.456% |
| RPG Life Sciences Limited | 1.28 Billion INR | -139.906% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 94.532% |
| Lupin Limited | 36.96 Billion INR | 91.684% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -351.059% |
| Wockhardt Limited | 1.08 Billion INR | -184.667% |
| Vaishali Pharma Limited | 31.71 Million INR | -9595.058% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 21.359% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -850.473% |
| Jubilant Pharmova Limited | 8 Billion INR | 61.599% |
| FDC Limited | 3.38 Billion INR | 9.186% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 96.517% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -969.636% |
| Eris Lifesciences Limited | 6.98 Billion INR | 55.995% |
| Venus Remedies Limited | 711.8 Million INR | -331.918% |
| ZIM Laboratories Limited | 462.09 Million INR | -565.315% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -107.866% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -1247.393% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 50.283% |
| Shilpa Medicare Limited | 2.58 Billion INR | -18.795% |
| Albert David Limited | 1.04 Billion INR | -194.082% |
| Ajanta Pharma Limited | 12.56 Billion INR | 75.533% |
| Hester Biosciences Limited | 539.47 Million INR | -469.893% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 34.268% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 208.948% |
| Gufic Biosciences Limited | 1.48 Billion INR | -107.662% |
| Windlas Biotech Limited | 781.72 Million INR | -293.287% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -6707.041% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -1657.342% |
| Granules India Limited | 8.6 Billion INR | 64.267% |
| Aarti Drugs Limited | 3.24 Billion INR | 5.363% |
| Bal Pharma Limited | 345.59 Million INR | -789.604% |
| Alkem Laboratories Limited | 24.19 Billion INR | 87.293% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 97.778% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -128.865% |
| Medicamen Biotech Limited | 245.66 Million INR | -1151.486% |
| Unichem Laboratories Limited | 742.35 Million INR | -314.141% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -2583.121% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -23556.51% |
| Valiant Laboratories Limited | 12.73 Million INR | -24033.762% |
| Orchid Pharma Limited | 1.41 Billion INR | -116.632% |
| Medico Remedies Limited | 129.09 Million INR | -2281.52% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 55.194% |
| Ipca Laboratories Limited | 13.29 Billion INR | 76.883% |
| Brooks Laboratories Limited | 41.72 Million INR | -7267.715% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -614.518% |
| Piramal Enterprises Limited | -3.86 Billion INR | 179.625% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 91.218% |
| NATCO Pharma Limited | 18.79 Billion INR | 83.642% |
| Suven Life Sciences Limited | -992.78 Million INR | 409.676% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 3816.32% |
| Strides Pharma Science Limited | 3.76 Billion INR | 18.336% |
| Indoco Remedies Limited | 2.64 Billion INR | -16.144% |
| Alpa Laboratories Limited | 229.96 Million INR | -1236.922% |
| Lasa Supergenerics Limited | -65.08 Million INR | 4824.032% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 182.391% |